ID   CMY
AC   CVCL_A602
DR   Cosmic; 787424
DR   Cosmic; 975242
DR   Cosmic; 996323
DR   Cosmic; 1012063
DR   Cosmic; 1037675
DR   Cosmic; 1191082
DR   Cosmic; 1281308
DR   Cosmic; 2089669
DR   Wikidata; Q54813866
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9852262;
RX   PubMed=10674912;
RX   PubMed=14504097;
RX   PubMed=16408098;
RX   PubMed=23955599;
CC   Population: Japanese.
CC   Doubling time: ~46 hours (PubMed=9852262).
CC   Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Tyr3Ter (c.9C>G); Zygosity=Unspecified (PubMed=23955599).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C2993; Down syndrome
DI   NCIt; C43223; Myeloid leukemia associated with Down syndrome
DI   ORDO; Orphanet_870; Down syndrome
DI   ORDO; Orphanet_99887; Acute megakaryoblastic leukemia in Down syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   2Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 16
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=9852262; DOI=10.3892/ijmm.1.3.559;
RA   Miura N., Sato T., Fuse A., Okimoto Y., Kinugawa N., Horie H., Ota S.,
RA   Kakuda H., Yokoe H., Miya T., Suzuki N., Niimi H.;
RT   "Establishment of a new human megakaryoblastic cell line, CMY, with
RT   chromosome 17p abnormalities.";
RL   Int. J. Mol. Med. 1:559-563(1998).
//
RX   PubMed=10674912; DOI=10.3109/10428190009148861;
RA   Sato T., Sekine H., Kakuda H., Miura N., Sunohara M., Fuse A.;
RT   "HIV infection of megakaryocytic cell lines.";
RL   Leuk. Lymphoma 36:397-404(2000).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//